Lifevantage Corporation · NASDAQ:LFVN
Lifevantage — Lifeline Therapeutics — Investor Presentation (April 2006)
25 slides from Lifevantage's investor presentation, Apr 6, 2006
Slide 1: Science-based solutions to oxidative stress
Dedicated to helping people reach their health and wellness goals through science-based solutions to oxidative stress science-based solutions to oxidative stress science-based solutions to oxidative stress science-based solutions to oxidative stress
Slide 2: Forward-looking statements
The issues addressed in this presentation may involve forward-looking statements which are subject to a number of risks and uncertainties. Actual results may differ materially. Please refer to our Annual Report and to our other SEC filings for more information about risks and uncertainties that coul
Slide 3: We are a science-based health and nutrition company
We are: A science-based health and nutrition company Committed to developing innovative products based on scientific evidence Our product: Patent-pending Protandim(r) strengthens natural antioxidant defenses to reduce the cell damage known as oxidative stress known as oxidative stress known as oxida
Slide 4: Corporate Overview
Public in October 2004, LFLT.OB Protandim(r) shipment begins March 2005 Protandim(r) featured on ABC Primetime Live June 2005 Human clinical trial study published January 2006 Additional product expansion opportunities Leading antioxidant research scientists Internationally renowned scientific advis
Slide 5: U.S. Market Opportunity -- 2006 estimate
U. S. Market Opportunity -- 2006 estimate Growing at 10% annually Source: Data Monitor November 2004 No Clinical Evidence Clinical Evidence $3.6 Billion segment $30 Billion Market
Slide 6: The Problem
Oxidative stress is associated with over 200 diseases, as presented in over a thousand peer-reviewed, published, scientific papers Examples of areas where oxidative stress appears to play a role, based on these papers, include: Heart disease Diabetes Cancer The Problem
Slide 7: Overview of Oxidative Stress
Oxidative stress (cell damage) occurs when oxidative balance is upset by increased production of oxidants, or by decreased availability of antioxidants Humans produce three antioxidant enzymes naturally: superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase Humans produce about 0.3
Slide 8: Yesterday's Solution
Consumable antioxidants (e.g., vitamins C and E) neutralize oxidants on a one-to-one relationship One gram of vitamin C per day can neutralize about 0.01 mole of superoxide per day An amount only 1/30th of the body's daily production This assumes full absorption and complete reaction prior to excret
Slide 9: Our Solution: Protandim
Protandim(r) - patent-pending formula Specifically formulated to strengthen the body's natural defenses against oxidative stress Delivers powerful antioxidant benefits in a whole new way Activates two key antioxidant enzymes - SOD and CAT - the body's own defense system against free radicals Deliver
Slide 10: The Scientific Evidence
The Scientific Evidence Free Radical Biology & Medicine (Jan. 15, 2006)
Slide 11: Protandim Study Results
TBARS are a key measure of oxidative stress TBARS are considered "the canary in the coal mine" After 30 days, 40% average reduction of TBARS After 120 days, increase in average antioxidant enzyme levels SOD +30% CAT +54% Protandim(r) Study Results
Slide 12: Protandim Study Conclusions
Causing modest induction of SOD and CAT to decrease oxidative stress and lipid peroxidation in vivo may be a much more effective approach than conventional antioxidant supplements. Protandim(r) Study Conclusions
Slide 13: Protandim
Increases the body's natural defense against oxidative stress by more than 30% Eliminates age related increase in oxidative stress Fights cellular aging from the inside out One caplet daily produces results within 30 days One caplet daily to maintain results Protandim(r) is the only product that has
Slide 14: Protandim Positioning
Science-based Market moving to evidence-based Clinically supported Premium product Science allows for premium pricing Protandim(r) Positioning
Slide 15: Protandim Patent-Pending
Aggressively working to obtain and protect Covers any combination of the identified botanical extracts Covers end outcome: induction of SOD and CAT and reduction of lipid peroxides Protandim(r) Patent-Pending
Slide 16: Corporate Strategy
Produce clinically tested products Protandim(r) product line expansion New products Based on science Science allows premium pricing "Partnership in Wellness" marketing campaign in development Partnering with leading companies to spread health and wellness message "Women's Initiative" Clinical lab te
Slide 17: Distribution Model
eCommerce Protandim(r) $49.95 retail 3-day DSO Autoship repeat customers Retail GNC Pursuing other potential partners Chain drug stores Health food stores Science allows partners to charge a premium Licensing + OEM + Partners Domestic and international Corporate Strategy Distribution Model
Slide 18: Product Promotions
Featured on ABC's Primetime Live June 2005 Consumer advertising Print and eCommerce - example targets include Wall Street Journal USA Today Prevention Newsweek New York Times Yoga Journal L. A. Times Delicious Living I Village Chicago Sun Times Women's Health Alternative Medicine Dallas Morning News
Slide 19: Product Promotions
Consumer advertising Radio National, regional Premiere Radio Networks Westwood One Networks TV Direct sales Direct response television Scandown supported Co-op supported Off-shelf display solutions Spokesperson(s) Co-branding promotion Corporate Strategy Product Promotions
Slide 20: Financial Model
Virtual company - low overhead Most costs variable eCommerce model provides strong cash flow Deferred revenue model approaching $1 million Exceptional Gross Margin On-demand production Financial Model
Slide 21: The Scientists
Joe M. McCord, Ph.D. Co-discoverer of SOD in 1969 Honorary President of the International Society of Antioxidants in Nutrition and Health (ISANH) Recipient of the prestigious Elliott Cresson Medal of the Franklin Institute Professor of Medicine at University of Colorado at Denver and Health Sciences
Slide 22: Scientific advisors
Larry Gold, PhD Founder, CEO, Chairman of the Board, and Chief Science Officer of SomaLogic, a leading clinical proteomics company Founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. Founded Synergen, Inc., a biotechnology compan
Slide 23: The Management
Stephen K. Onody, CEO 28 years of experience in healthcare companies Chairman and CEO, Colorado MEDTech, Inc. (NASDAQ: CMED) Vital Signs, Microphage, Boston Scientific Recipient of entrepreneurial and leadership awards Gerald J. Houston, CFO Founder and CFO, OpVista, Inc. ROLM, IBM, Measurex, KPMG S
Slide 24: The Board of Directors
Javier Baz, Chairman Private Investor, former investment banker Dr. James Crapo Former Chairman of Medicine, National Jewish Medical and Research Center James J. Krejci Exec. Director, Epilepsy Foundation of Colorado Bill Lister Ret. Senior VP and General Manager Patient Care, Roche Diagnostics Corp
Slide 25: The Future
The Future Grow Protandim(r): eCommerce + Retail Licensing + OEM International Distribution "Partnership in Wellness" Additional Products: Science-based
Lifeline Therapeutics — Investor Presentation (April 2006) on 6ix